drugset
Drugs / Sintilimab
last change 3 days ago re-read 2 minutes ago

Sintilimab

also known as IBI308 · PD1 antibody · Tyvyt · Sintilimab Injection · ANTI-PD-1 MONOCLONAL ANTIBODY IBI308 · Darbersol · Sin · Sindilizumab · +3 more

Monoclonal antibody targets PDCD1 via inhibition

Developed for
hepatocellular carcinoma · non-small cell lung carcinoma · gastric cancer · colorectal cancer · esophageal squamous cell carcinoma · cancer · rectal cancer · gastroesophageal adenocarcinoma
+109 more · gastroesophageal junction adenocarcinoma · nasopharyngeal carcinoma · extranodal nasal NK/T cell lymphoma · head and neck squamous cell carcinoma · gastric adenocarcinoma · lung cancer · small cell lung carcinoma · intrahepatic cholangiocarcinoma · malignant pancreatic neoplasm · metastasis from malignant tumor of colon · diffuse large B-cell lymphoma · neoplasm · renal cell carcinoma · triple-negative breast carcinoma · biliary tract cancer · cervical cancer · endometrial cancer · esophageal cancer · gastric neoplasm · oral cavity squamous cell carcinoma · rectum adenocarcinoma · colorectal carcinoma · neuroendocrine carcinoma · non-small cell squamous lung carcinoma · portal vein thrombosis · soft tissue sarcoma · adenocarcinoma · anal squamous cell carcinoma · breast cancer · cancer of unknown primary site · classic Hodgkin lymphoma · colon carcinoma · colorectal adenocarcinoma · glioblastoma · lung carcinoma · mature T-cell and NK-cell non-Hodgkin lymphoma · metastatic malignant neoplasm · metastatic neoplasm · oropharynx squamous cell carcinoma · primary central nervous system lymphoma · cervical carcinoma · childhood malignant neoplasm · cholangiocarcinoma · chronic hepatitis B virus infection · gastric carcinoma · gastroesophageal cancer · metastatic malignant neoplasm in the brain · nasopharyngeal neoplasm · neoplastic disease or syndrome · neuroblastoma · peripheral T-cell lymphoma, not otherwise specified · peritoneal carcinomatosis · primary cutaneous T-cell lymphoma · rectal carcinoma · acral lentiginous melanoma · AIDS · anal canal cancer · angioimmunoblastic T-cell lymphoma · angiosarcoma · appendix carcinoma · carcinoma · carcinoma of esophagus · central nervous system non-hodgkin lymphoma · clear cell renal carcinoma · colonic neoplasm · colorectal neoplasm · combined hepatocellular carcinoma and cholangiocarcinoma · cutaneous melanoma · digestive system cancer · digestive system neoplasm · endometrioid adenocarcinoma · endometrium adenocarcinoma · Epstein-Barr virus infection · exocrine pancreatic carcinoma · follicular lymphoma · gallbladder cancer · hemophagocytic syndrome · hepatoblastoma · hepatoid adenocarcinoma · inborn disorder of energy metabolism · liver cancer · lung neoplasm · lymphoepithelioma-like lung carcinoma · malignant epithelial tumor of salivary glands · malignant leptomeningeal tumor · malignant peritoneal mesothelioma · malignant pleural mesothelioma · mantle cell lymphoma · meningioma · mucosal melanoma · nasal cavity and paranasal sinus carcinoma · neuroendocrine neoplasm · oral cavity cancer · ovarian cancer · ovarian clear cell adenocarcinoma · ovarian clear cell cancer · pancreas disorder · pancreatic exocrine neoplasm · peritoneal neoplasm · primary mediastinal large B-cell lymphoma · small intestine adenocarcinoma · thoracic cancer · thyroid cancer · thyroid tumor · transitional cell neoplasm · tumor of salivary gland · undifferentiated pleomorphic sarcoma · Hodgkins lymphoma · peritoneal mesothelioma
Investigated by
Innovent Biologics (Suzhou) Co. Ltd. · Sun Yat-sen University · Fudan University · Tianjin Medical University Cancer Institute and Hospital · Zhejiang Cancer Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
+289 more · The First Affiliated Hospital with Nanjing Medical University · Second Affiliated Hospital, School of Medicine, Zhejiang University · West China Hospital · Henan Cancer Hospital · Second Affiliated Hospital of Guangzhou Medical University · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhejiang University · Peking Union Medical College Hospital · Ruijin Hospital · Shanghai Zhongshan Hospital · Chinese PLA General Hospital · Fujian Cancer Hospital · Sichuan University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The First Hospital of Jilin University · Nanfang Hospital, Southern Medical University · RenJi Hospital · The First Affiliated Hospital of Zhengzhou University · Chinese Academy of Medical Sciences · Guangdong Provincial People's Hospital · Peking University Cancer Hospital & Institute · Qilu Hospital of Shandong University · Shandong Cancer Hospital and Institute · Shanghai Chest Hospital · Xin-Hua Xu · Hebei Medical University Fourth Hospital · Hunan Province Tumor Hospital · Innovent Biologics, Inc. · Peking University · Peking University People's Hospital · Sichuan Cancer Hospital and Research Institute · Sixth Affiliated Hospital, Sun Yat-sen University · Tang-Du Hospital · Xiangya Hospital of Central South University · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Anhui Provincial Cancer Hospital · Beijing 302 Hospital · Beijing Friendship Hospital · Beijing Tongren Hospital · China Medical University, China · Fifth Affiliated Hospital, Sun Yat-Sen University · First Affiliated Hospital of Zhejiang University · First Affiliated Hospital, Sun Yat-Sen University · First People's Hospital of Foshan · Guangdong Association of Clinical Trials · Hangzhou Neoantigen Therapeutics Co., Ltd. · Hubei Cancer Hospital · Hutchmed · M.D. Anderson Cancer Center · Shanghai Changzheng Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Shengjing Hospital · Sun Yat-sen University Cancer Center · The First Affiliated Hospital of Soochow University · The First Affiliated Hospital of Xiamen University · Third Affiliated Hospital, Sun Yat-Sen University · Affiliated Hospital of Guangdong Medical University · Aiping Zhou · Beijing Bethune Charitable Foundation · Beijing Hospital · Beijing Tsinghua Chang Gung Hospital · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chongqing Three Gorges Central Hospital · Eastern Hepatobiliary Surgery Hospital · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Chongqing Medical University · First Affiliated Hospital of Fujian Medical University · First Affiliated Hospital of Guangxi Medical University · GeneCast Biotechnology Co., Ltd. · Harbin Medical University · Huazhong University of Science and Technology · Jiangsu Cancer Institute & Hospital · Jingzhou Central Hospital · all 295 on the full record

Trials 565 · started per year

today
1
4
15
63
54
93
75
57
89
59
55
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT06497010 Aug 2024 → Jul 2026 overdue neoplasm The Affiliated Hospital Of Guizhou Medical University Recruiting No outcome recorded
Phase 0 NCT04412408 Sep 2020 → Dec 2022 neuroblastoma Shanghai Children's Medical Center Unknown No outcome recorded
Phase 0 NCT03940001 May 2019 → May 2021 esophageal squamous cell carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 140 trials
Phase 1 NCT07457281 Apr 2026 → Apr 2027 expected head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT07455617 Mar 2026 → Jun 2029 expected metastatic neoplasm Suzhou Abogen Biosciences Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT07411781 Mar 2026 → Mar 2027 expected colorectal cancer Chinese PLA General Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06793956 Feb 2025 → Jan 2026 overdue extranodal nasal NK/T cell lymphoma Sun Yat-sen University Recruiting No outcome recorded
Phase 1 NCT06431685 Apr 2024 → Mar 2025 overdue malignant leptomeningeal tumor, non-small cell lung carcinoma Sichuan University Recruiting No outcome recorded
Phase 1 NCT05718219 Mar 2023 → Dec 2025 overdue neoplasm Jiangsu Simcere Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT05427487 Feb 2023 → Jun 2028 expected colorectal cancer, gastric cancer, ovarian cancer ImmVirx Pty Ltd Recruiting No outcome recorded
Phase 1 NCT05225116 Jan 2023 → Dec 2025 hepatocellular carcinoma Beijing Tsinghua Chang Gung Hospital Unknown No outcome recorded
Phase 1 NCT05504278 Sep 2022 → May 2025 overdue non-small cell lung carcinoma Innovent Biologics (Suzhou) Co. Ltd. Recruiting No outcome recorded
Phase 1 NCT05245916 Apr 2022 → Aug 2023 cancer Innovent Biologics (Suzhou) Co. Ltd. Withdrawn No outcome recorded
Phase 1/243 trials
Phase 1/2 NCT07714317 Jul 2026 → Jul 2027 expected hepatocellular carcinoma Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT07612137 Jun 2026 → Jun 2027 expected cancer Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07579247 May 2026 → Dec 2029 expected AIDS Shanghai Public Health Clinical Center Not yet recruiting No outcome recorded
Phase 1/2 NCT07522411 Apr 2026 → Dec 2027 expected hepatocellular carcinoma BinYong Liang Not yet recruiting No outcome recorded
Phase 1/2 NCT07131202 Jan → Dec 2026 expected cancer Suzhou Forlong Biotechnology Co., Ltd Recruiting No outcome recorded
Phase 1/2 NCT07190027 Nov 2025 overdue non-small cell lung carcinoma First Affiliated Hospital of Wenzhou Medical University Not yet recruiting No outcome recorded
Phase 1/2 NCT06995105 Apr 2025 → Apr 2027 expected hepatocellular carcinoma Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT06956716 Apr 2025 → Apr 2027 expected intrahepatic cholangiocarcinoma Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT06888674 Apr 2025 → Apr 2027 expected pancreas disorder Zhejiang University Not yet recruiting No outcome recorded
Phase 1/2 NCT06742411 Dec 2024 → Dec 2026 expected gastric cancer West China Hospital Recruiting No outcome recorded
Phase 2386 trials
Phase 2 NCT07602140 Aug 2026 → Aug 2028 expected gastric cancer Shandong Provincial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07715565 Aug 2026 → Dec 2029 expected renal cell carcinoma West China Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07645846 Jul 2026 → Aug 2028 expected nasal cavity and paranasal sinus carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07656766 Jul 2026 → Sep 2027 expected colorectal cancer Peking University People's Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07683221 Jul 2026 → Jul 2029 expected malignant pancreatic neoplasm Shandong Cancer Hospital and Institute Not yet recruiting No outcome recorded
Phase 2 NCT07669740 Jul 2026 → Jun 2027 expected gastric cancer The First Affiliated Hospital with Nanjing Medical University Not yet recruiting No outcome recorded
Phase 2 NCT07685704 Jul 2026 → Jun 2028 expected gastric cancer, gastroesophageal junction adenocarcinoma Zhifeng Zhao, PhD Not yet recruiting No outcome recorded
Phase 2 NCT07638631 Jun 2026 → Dec 2028 expected gastric cancer Chen Lizhu Not yet recruiting No outcome recorded
Phase 2 NCT07535632 Jun 2026 → Jun 2028 expected colorectal neoplasm Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07603661 Jun 2026 → Jun 2028 expected non-small cell lung carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Show all 386 trials opens the full record — a long page
Phase 2/314 trials
Phase 2/3 NCT07643623 Jun 2026 → Dec 2031 expected adenocarcinoma Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Not yet recruiting No outcome recorded
Phase 2/3 NCT07319429 Jan 2026 → Dec 2027 expected endometrial cancer, infertility disorder Fudan University Recruiting No outcome recorded
Phase 2/3 NCT06977061 Jun 2025 → Jun 2026 overdue gastric neoplasm Queling Liu Not yet recruiting No outcome recorded
Phase 2/3 NCT06138028 Sep 2023 → Oct 2025 overdue esophageal squamous cell carcinoma Qingdao Central Hospital Recruiting No outcome recorded
Phase 2/3 NCT05522231 Oct 2022 → Jan 2025 overdue renal cell carcinoma Hutchmed Active not recruiting No outcome recorded
Phase 2/3 NCT05484024 Aug 2022 → Jul 2028 expected rectal cancer Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 2/3 NCT05250843 May 2022 → Dec 2023 hepatocellular carcinoma Third Affiliated Hospital, Sun Yat-Sen University Unknown No outcome recorded
Phase 2/3 NCT05322187 Apr 2022 → Sep 2023 childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm RenJi Hospital Unknown No outcome recorded
Phase 2/3 NCT05002686 Aug 2021 → Aug 2023 gastric cancer Ruijin Hospital Unknown No outcome recorded
Phase 2/3 NCT04322617 Mar 2020 → Mar 2028 expected non-small cell lung carcinoma Hunan Province Tumor Hospital Recruiting No outcome recorded
Phase 346 trials
Phase 3 NCT07678229 Jul 2026 → Dec 2031 expected mature T-cell and NK-cell non-Hodgkin lymphoma Rong Tao Not yet recruiting No outcome recorded
Phase 3 NCT07537946 May 2026 → May 2031 expected hepatocellular carcinoma, metastatic neoplasm Tongji Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07692152 Mar 2026 → Mar 2029 expected anal squamous cell carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 3 NCT07459296 Mar 2026 → Apr 2030 expected nasopharyngeal carcinoma First Affiliated Hospital of Guangxi Medical University Recruiting No outcome recorded
Phase 3 NCT07371611 Jan 2026 → Dec 2030 expected oral cavity squamous cell carcinoma Qunxing Li,MD Recruiting No outcome recorded
Phase 3 NCT07186621 Jul 2025 → Jul 2027 expected hepatocellular carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 3 NCT06794086 Apr 2025 → Jun 2026 overdue metastasis from malignant tumor of colon Jun Huang Recruiting No outcome recorded
Phase 3 NCT06791512 Jan 2025 → Dec 2030 expected colorectal adenocarcinoma Jun Huang Recruiting No outcome recorded
Phase 3 NCT06584032 Dec 2024 → Jan 2029 expected endometrial cancer Hutchmed Recruiting No outcome recorded
Phase 3 NCT06497985 Dec 2024 → May 2028 expected colorectal cancer Chipscreen Biosciences, Ltd. Recruiting No outcome recorded
Phase 45 trials
Phase 4 NCT07010393 Jul 2025 → Dec 2027 expected thyroid tumor Fujian Medical University Not yet recruiting No outcome recorded
Phase 4 NCT06931808 Mar 2025 → Mar 2026 overdue rectum adenocarcinoma First Affiliated Hospital of Ningbo University Enrolling by invitation No outcome recorded
Phase 4 NCT06499610 Jul 2024 → Oct 2027 expected gastric cancer First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
Phase 4 NCT05843292 Jul 2023 → Dec 2024 overdue triple-negative breast carcinoma Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 4 NCT05312840 Jan 2022 → Dec 2024 non-small cell lung carcinoma People's Hospital of Quzhou Completed No outcome recorded
Phase not applicable28 trials
— NCT07542912 Jun 2026 → Jun 2029 expected — Sun Yat-sen University Not yet recruiting No outcome recorded
— NCT07350824 Dec 2025 → Dec 2027 expected hepatocellular carcinoma Tongji Hospital Not yet recruiting No outcome recorded
— NCT07474103 Nov 2025 → Mar 2028 expected rectum adenocarcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
— NCT07077798 Aug 2025 → Aug 2026 overdue hepatocellular carcinoma Wan-Guang Zhang Not yet recruiting No outcome recorded
— NCT07067450 Jul 2025 → Dec 2026 expected esophageal squamous cell carcinoma Sichuan University Not yet recruiting No outcome recorded
— NCT06740370 Dec 2024 → Dec 2025 overdue hepatocellular carcinoma Sun Yat-sen University Recruiting No outcome recorded
— NCT06622031 Oct 2024 → Dec 2026 expected hepatocellular carcinoma, portal vein thrombosis Sun Yat-sen University Recruiting No outcome recorded
— NCT06549855 Oct 2024 → Jul 2029 expected endometrial cancer, endometrioid adenocarcinoma Peking University People's Hospital Not yet recruiting No outcome recorded
— NCT06457477 Jun 2024 → Dec 2025 chronic hepatitis B virus infection Beijing 302 Hospital Unknown No outcome recorded
— NCT06070636 May 2024 → Jan 2025 overdue hepatocellular carcinoma Sun Yat-sen University Recruiting No outcome recorded
Also used as a comparator or background therapy in 86 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06347198 Background Apr → Dec 2024 colorectal cancer Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
Phase 114 trials
Phase 1 NCT07699757 Background Jul 2026 → Apr 2029 expected non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Haisco Pharmaceutical Group Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT07557251 Background May 2026 → Dec 2028 expected hepatocellular carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1 NCT06896422 Background Jun 2025 → Dec 2026 expected non-small cell lung carcinoma The First Affiliated Hospital of Zhengzhou University Recruiting No outcome recorded
Phase 1 NCT06773312 Background Feb 2025 → Oct 2026 expected gastroesophageal junction adenocarcinoma Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT05979818 Background Nov 2024 → Aug 2025 overdue non-small cell lung carcinoma Second Xiangya Hospital of Central South University Recruiting No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT07072351 Background Sep 2025 → May 2028 expected gastroesophageal junction adenocarcinoma West China Hospital Recruiting No outcome recorded
Phase 1/2 NCT07025889 Background Jun 2025 → Jun 2026 overdue gastric cancer Ruijin Hospital Recruiting No outcome recorded
Phase 1/2 NCT06888648 Background Apr 2025 → Apr 2027 expected malignant pancreatic neoplasm Zhejiang University Not yet recruiting No outcome recorded
Phase 1/2 NCT06329973 Background Feb 2024 → Jun 2026 overdue gastroesophageal junction adenocarcinoma Henan Cancer Hospital Recruiting No outcome recorded
Phase 1/2 NCT05632939 Background Feb 2023 → Oct 2025 overdue gastric cancer, gastroesophageal cancer AskGene Pharma, Inc. Active not recruiting No outcome recorded
Phase 241 trials
Phase 2 NCT07658872 Background Jun 2026 → May 2027 expected gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Sichuan University Not yet recruiting No outcome recorded
Phase 2 NCT07638501 Background Jun 2026 → Jun 2028 expected biliary tract cancer Eastern Hepatobiliary Surgery Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07621562 Background Jun 2026 → Sep 2027 expected gastric adenocarcinoma, gastroesophageal junction adenocarcinoma First Affiliated Hospital of Zhejiang University Not yet recruiting No outcome recorded
Phase 2 NCT07646639 Background May 2026 → Dec 2028 expected rectal cancer The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT07537972 Background May 2026 → May 2029 expected hepatocellular carcinoma, metastatic carcinoma in the bone Tongji Hospital Not yet recruiting No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT07490262 Background Mar 2026 → Dec 2027 expected hepatocellular carcinoma Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Recruiting No outcome recorded
Phase 2/3 NCT07076693 Background Jun 2025 → May 2028 expected non-small cell lung carcinoma Shanghai Chest Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT05976568 Comparator Sep 2023 → Sep 2027 expected hepatocellular carcinoma Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 2/3 NCT04702009 Background Jan 2021 → Oct 2025 non-small cell lung carcinoma Shanghai Pulmonary Hospital, Shanghai, China Completed No outcome recorded
Phase 2/3 NCT05809336 Background May 2019 → Oct 2022 neoplasm Beijing Friendship Hospital Completed No outcome recorded
Phase 310 trials
Phase 3 NCT07686796 Background Jan 2027 → Jan 2030 expected rectal cancer Guangdong Provincial People's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07677293 Comparator Jun 2026 → Dec 2028 expected adenocarcinoma Peking University Not yet recruiting No outcome recorded
Phase 3 NCT07584135 Comparator May 2026 → Jan 2029 expected gastric adenocarcinoma NingBo Junyan Hongshi Biosciences Co., Ltd Recruiting No outcome recorded
Phase 3 NCT06900218 Background May 2025 → May 2030 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT06925243 Comparator Apr 2025 → Dec 2027 expected gastroesophageal adenocarcinoma Zuoyi Jiao Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT06761911 Comparator Dec 2024 → Dec 2025 overdue Hodgkins lymphoma Xiuhua Sun Not yet recruiting No outcome recorded
Phase not applicable9 trials
— NCT07330271 Comparator Dec 2025 → Nov 2029 expected peritoneal mesothelioma Beijing Tsinghua Chang Gung Hospital Recruiting No outcome recorded
— NCT06702566 Background Jul 2024 → Jul 2026 overdue acute leukemia, cancer Tianjin Medical University Cancer Institute and Hospital Recruiting No outcome recorded
— NCT06357806 Comparator May 2024 → Oct 2026 expected chronic hepatitis B virus infection Beijing 302 Hospital Active not recruiting No outcome recorded
— NCT06349044 Background Mar 2024 → Dec 2025 overdue biliary tract cancer, colorectal adenocarcinoma, hepatocellular carcinoma Zhejiang Cancer Hospital Recruiting No outcome recorded
— NCT06512207 Comparator Dec 2023 → Dec 2025 overdue non-small cell lung carcinoma Jinzhou Medical University Recruiting No outcome recorded

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 657 sources stand behind the page.

FieldValueCited text
Known as Sintilimab “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗
632

“Once stable disease is confirmed by two consecutive radiological assessments, sintilimab (200 mg intravenously every three weeks) is added as maintenance treatment until...” NCT07637448 ↗

“Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Oxaliplatin 130mg/m2+Capecitabine 1250mg/m2 for 6-8cycles, Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Capecitabine 1250mg/m2 as maintenance...” NCT06973343 ↗

“Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22...” NCT06250894 ↗

“Our prior findings demonstrated that the combination of autologous NK cells with the PD-1 antibody (Sintilimab), offered promising efficacy in NSCLC patients who failed the...” PMID 40469279 ↗ May 2025

“The patients in the postoperative adjuvant treatment cohort received regular PD-1 inhibitor adjuvant therapy (Sintilimab), once every 21 days, for a total of 8 times, and...” NCT07350824 ↗

“Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗

“The purpose of this study was to evaluate the effect of capecitabine-based long-term radiotherapy followed by 3 cycles Sintilimab (PD-1 inhibitor) in patients with locally...” NCT06493240 ↗

“Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days...” NCT07678229 ↗

“Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or...” NCT07076693 ↗

“The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once...” NCT06728657 ↗

“Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.” NCT06752382 ↗

“Eligible patients will receive 3-4 cycles of Sintilimab combined with platinum-based doublet induction chemotherapy, followed by assessment for feasibility of radical lung resection.” NCT06962189 ↗

“The treatment option for the chidamide + sintilimab + bevacizumab (study group) is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W” NCT05768503 ↗

“ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗

“Potential options include Sintilimab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.” NCT06468280 ↗

“The PD-1 inhibitor component is not fixed; specific agents (such as pembrolizumab, sintilimab, etc.) may be used according to institutional standards and drug availability.” NCT07417501 ↗

“The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.” NCT06916117 ↗

“Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.” PMID 40055652 ↗ Mar 2025

“Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery” NCT05157776 ↗

“Examples include PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab, camrelizumab, sintilimab) Administered per standard dosing schedule (e.g., every 2-3 weeks)” NCT07277777 ↗

“Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started within 7 days after the first DEB-TACE+HAIC.” NCT06904183 ↗

“Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W” NCT06170710 ↗

“Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)” NCT06740370 ↗

“200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.” NCT06342167 ↗

“Treatment comprised up to eight 21-day cycles of sintilimab 200 mg (day 1), pegaspargase 2500 IU/m2 (day 1), and anlotinib 8 mg (days 1-14)” PMID 41774854 ↗ Mar 2026

“Participants will receive either tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in period of one to three cycles.” NCT06497010 ↗

“Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma” PMID 36872337 ↗ Mar 2023

“In the Sin-Bev-TACE arm, sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) will be started at 3-7 days after the first TACE.” NCT05985798 ↗

“including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).” NCT04110093 ↗

“disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle” NCT05113459 ↗

“The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1.” NCT06794086 ↗

“PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks.” NCT06991907 ↗

“a fixed 200 mg dose of a PD-1 inhibitor (Sintilimab, Tislelizumab, or Toripalimab) is administered via intra-arterial injection” NCT07504471 ↗

“Sintilimab, a human immunoglobulin G4 monoclonal antibody for programmed cell death-1, has shown efficacy in various cancers.” PMID 37052821 ↗ Apr 2023

“systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion” NCT04814043 ↗

“PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab, Nivolumab), 200mg/dose, iv drip, q3w.” NCT07537985 ↗

“The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.” NCT06184841 ↗

“All eligible patients will be treated with sintilimab combined with pegaspargase administered every 3 weeks for 4 cycles” NCT04676789 ↗

“Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.” NCT04989985 ↗

“Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on” NCT06032052 ↗

“Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.).” NCT05248022 ↗

“Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab.” NCT05233358 ↗

“PD-1 inhibitors in this study include, but not limited to, Pembrolizumab, nivolumab, sintilimab, toripalimab, etc.” NCT05509478 ↗

“All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.” NCT06426654 ↗

“Patients were enrolled and received sintilimab (200 mg) plus bevacizumab (7.5 mg/kg) intravenously every 3 weeks.” PMID 37593221 ↗ Aug 2023

“PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;” NCT05721651 ↗

“PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab), 200mg/dose, iv drip, q3w.” NCT07501351 ↗

“PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.” NCT06702566 ↗

“fixed dose of either terriplizumab injection (Toripalimab) or Sintilimab injection (Darbersol, Sintilimab).” NCT06078670 ↗

“Subjects receive anti-PD-1 antibody (Sintilimab) via intravenous infusion throughout the treatment period.” NCT07648069 ↗

“in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w).” NCT06665087 ↗

“PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.” NCT05777707 ↗

“Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab” NCT06405113 ↗

“for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment” NCT06592612 ↗

“Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection.” NCT05247996 ↗

“Arm B：Cetuximab β (500mg/m2,iv,d1,q2w）+Fruquintinib（5mg, po, qd, 2w/1w）+Sintilimab（200mg, iv, d1, q3w）；” NCT07257653 ↗

“Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗

“Additionally, if the tumor tests positive for PD-L1 (≥1%), the immunotherapy drug sintilimab is added.” NCT07330271 ↗

“Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd” NCT06580574 ↗

“Sintilimab: 200 mg administered by intravenous infusion (over 30-60 minutes) on Day 1 of each cycle.” NCT07239622 ↗

“The PD-1 monoclonal antibody used is Sintilimab 200mg, administered intravenously on the first day.” NCT06767007 ↗

“Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor.” NCT04663763 ↗

“Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W.” NCT06121700 ↗

“Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.” NCT04997837 ↗

“Sintilimab is a recombinant fully humanized anti-programmed death 1 (PD1) monoclonal antibody.” NCT03758001 ↗

“a PD-1 inhibitor (sintilimab) as maintenance therapy in patients with advanced gastric cancer” NCT06957977 ↗

“All enrolled participants will receive FL115 and Sintilimab via intravenous (IV) infusion.” NCT07131202 ↗

“The group A was treated with endostar,sintilimab and chemotherapy(carboplatin-pemetrexed).” NCT04063449 ↗

“four cycles of CAPOX chemotherapy plus sintilimab (anti-PD-1 immunotherapy), then surgery” NCT07161115 ↗

“Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip” NCT04512534 ↗

“combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous)” NCT06791512 ↗

“Sintilimab 200 mg administered by intravenous infusion on Day 1 of each 3-week cycle.” NCT07072351 ↗

“atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on” NCT04135690 ↗

“Sintilimab injection: 100 mg (10 mL) per vial; 200 mg intravenously every 3 weeks” NCT07492342 ↗

“Alternatively, sintilimab 200 mg Q3W may be used at investigator's discretion.” NCT07685704 ↗

“Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w” NCT05400070 ↗

“Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less” NCT07177105 ↗

“PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT” NCT05374252 ↗

“After lymphodepletion, patients are infused GC101 TIL followed sintilimab.” NCT05417750 ↗

“Sintilimab (IBI308) is a recombinant human IgG4 PD-1 monoclonal antibody.” NCT03869034 ↗

“Pembrolizumab, Sintilimab etc. have been used in the previous treatment.” NCT04322617 ↗

“Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.” NCT04764006 ↗

“Sintilimab will be administered 200 mg intravenous drip, every 3 weeks.” NCT04098796 ↗

“e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab” NCT06896422 ↗

“Sintilimab was employed for immunotherapy at a fixed dose of 200mg.” NCT07385664 ↗

“Sintilimab is an antibody against programmed cell death protein 1.” PMID 38106561 ↗ Oct 2023

“Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC” NCT06397222 ↗

“Sintilimab plus bevacizumab plus platinum-doublet chemotherapy” NCT06775743 ↗

“Sintilimab will be administered at 200 mg i.v. every 3 weeks.” NCT05098847 ↗

“PD-1 inhibitor (Sintilimab) and PCSK9 inhibitor (Tafolecimab)” NCT06304987 ↗

“Sintilimab Injection，Intravenous infusion，200mg，3-week cycle” NCT05402722 ↗

“PD-1 Inhibitor (e.g.pembrolizumab, Sintilimab,Camrelizumab )” NCT05322187 ↗

“Sintilimab injection (hereinafter referred to as Sintilimab)” NCT05949775 ↗

“Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles” NCT05468138 ↗

“Intravenous administration of Sintilimab (1200mg/3weeks)” NCT03994744 ↗

“Sintilimab: intravenous infusion, 200mg, on day 1, q3w.” NCT06195670 ↗

“mFOLFOX6+Bevacizumab+Sintilimab treatment combinations” NCT04895137 ↗

“Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab” NCT05476965 ↗

“sintilimab is an anti-PD-1 monoclonal antibody.” PMID 35623659 ↗ May 2022

“PD-1 inhibitor (sintilimab) neoadjuvant therapy” NCT04769076 ↗

“sintilimab 200 mg/m² IV infusion on Day 1, q3w” NCT07581626 ↗

“Sintilimab (200mg intravenously every 3 weeks)” NCT06622031 ↗

“Sintilimab Injection 200mg，intravenous drip，d1” NCT06499610 ↗

“sintilimab (200 mg intravenous infusion, q3w)” NCT07522411 ↗

“Sintilimab： 200mg i.v., d1, 21days one cycle” NCT04885413 ↗

“αPD-1 (half-dose sintilimab) add-on therapy” PMID 41443982 ↗ Jul 2026

“P-P-GemOx regimen Sintilimab 200mg iv D1;” NCT06824883 ↗

“Sintilimab,200mg, d1, intravenous drip” NCT06412068 ↗

“Sintilimab : 200mg , d1 , ivdrip , q3w” NCT07602140 ↗

“Drug: Sintilimab, 200mg, Q3W, C1C2C3.” NCT07645846 ↗

“Combined With Sintilimab 200mg/time” NCT04192682 ↗

“Sintilimab: weight \< 60kg, 3mg/kg” NCT06094868 ↗

“Drug: Sintilimab, 200mg IV D1 Q3W” NCT06714708 ↗

“200mg sintilimab and radiotherapy” NCT05774275 ↗

“Drug: Sintilimab, 200mg IV D1 Q3W” NCT07138755 ↗

“Sintilimab or Tislelizumab, Q3w” NCT07677293 ↗

“Sintilimab 200 mg ivdrip, Q3W” NCT05400902 ↗

“Sintilimab Injection 200mg d4” NCT05164978 ↗

“chemotherapy and sintilimab” NCT07555678 ↗

“Sintilimab: 200mg IV, day 1” NCT04300959 ↗

“Sintilimab 200mg d1 iv q3w” NCT06349044 ↗

“Sintilimab (200mg d1，q3w)” NCT06120127 ↗

“Sintilimab (200mg, D1)” NCT07542912 ↗

“Sintilimab: 200mg, iv；” NCT06487429 ↗

“Sintilimab Injection” NCT07319429 ↗

“Sintilimab Injection” NCT05699811 ↗

“Sintilimab injection” NCT05809336 ↗

“Drug: Sintilimab” NCT07179900 ↗

“Sintilimab” NCT04872582 ↗

“Sintilimab” NCT06031597 ↗

“Sintilimab” NCT05008861 ↗

“Sintilimab” NCT05913661 ↗

“Sintilimab” NCT06928584 ↗

“Sintilimab” NCT05307198 ↗

NCT06365008 ↗

NCT05638451 ↗

NCT06456515 ↗

NCT04167657 ↗

NCT03812549 ↗

NCT06078657 ↗

NCT04387500 ↗

NCT05835245 ↗

NCT07018063 ↗

NCT05572463 ↗

NCT06050317 ↗

NCT04899427 ↗

NCT04213170 ↗

NCT06353646 ↗

NCT06494943 ↗

NCT06123455 ↗

NCT07506109 ↗

NCT05346146 ↗

NCT05162352 ↗

NCT07061535 ↗

NCT07010393 ↗

NCT04984980 ↗

NCT05292417 ↗

NCT06584032 ↗

NCT07351487 ↗

NCT05251662 ↗

NCT07268677 ↗

NCT05029973 ↗

NCT06314334 ↗

NCT04055792 ↗

NCT05161572 ↗

NCT06680115 ↗

NCT04882462 ↗

NCT04312204 ↗

NCT04796025 ↗

NCT06408623 ↗

NCT04720716 ↗

NCT07328802 ↗

NCT05136768 ↗

NCT04809779 ↗

NCT07557251 ↗

NCT05225116 ↗

NCT06759064 ↗

NCT06973330 ↗

NCT06033118 ↗

NCT03983759 ↗

NCT05524155 ↗

NCT06543069 ↗

NCT06190639 ↗

NCT05795296 ↗

NCT06031285 ↗

NCT06577194 ↗

NCT06457477 ↗

NCT06761027 ↗

NCT04212598 ↗

NCT04513301 ↗

NCT04967625 ↗

NCT04104074 ↗

NCT07400302 ↗

NCT06709417 ↗

NCT07379424 ↗

NCT06220318 ↗

NCT03863483 ↗

NCT06158919 ↗

NCT04400851 ↗

NCT06070636 ↗

NCT04326153 ↗

NCT03545971 ↗

NCT04167293 ↗

NCT07352007 ↗

NCT05162872 ↗

NCT05504278 ↗

NCT06543836 ↗

NCT04514835 ↗

NCT06761911 ↗

NCT05170581 ↗

NCT06121505 ↗

NCT04052659 ↗

NCT04702009 ↗

NCT07120698 ↗

NCT03985046 ↗

NCT06620822 ↗

NCT06730373 ↗

NCT04106180 ↗

NCT04547452 ↗

NCT06925243 ↗

NCT04636008 ↗

NCT06512467 ↗

NCT04398927 ↗

NCT05468177 ↗

NCT06808412 ↗

NCT04089657 ↗

NCT05250843 ↗

NCT04728724 ↗

NCT07515625 ↗

NCT04973293 ↗

NCT05235906 ↗

NCT06013618 ↗

NCT06213519 ↗

NCT07518602 ↗

NCT05718219 ↗

NCT07560488 ↗

NCT05753163 ↗

NCT04956146 ↗

NCT05653180 ↗

NCT06512207 ↗

NCT07474103 ↗

NCT04459611 ↗

NCT04728568 ↗

NCT06227325 ↗

NCT07350850 ↗

NCT04304209 ↗

NCT04790409 ↗

NCT05057052 ↗

NCT05507632 ↗

NCT06604351 ↗

NCT05940181 ↗

NCT07521852 ↗

NCT05757336 ↗

NCT05438108 ↗

NCT04592029 ↗

NCT06895577 ↗

NCT05562297 ↗

NCT07186621 ↗

NCT06468670 ↗

NCT07612137 ↗

NCT06383559 ↗

NCT07067450 ↗

NCT05781074 ↗

NCT06572813 ↗

NCT07715565 ↗

NCT05170503 ↗

NCT07455617 ↗

NCT05116462 ↗

NCT04202601 ↗

NCT03228836 ↗

NCT04589754 ↗

NCT06054906 ↗

NCT04052152 ↗

NCT06468644 ↗

NCT03607539 ↗

NCT06848569 ↗

NCT04590599 ↗

NCT06977061 ↗

NCT06590259 ↗

NCT07053150 ↗

NCT05549037 ↗

NCT06685276 ↗

NCT05625737 ↗

NCT05481476 ↗

NCT05519410 ↗

NCT07683221 ↗

NCT05781386 ↗

NCT03802240 ↗

NCT07152769 ↗

NCT04958473 ↗

NCT06281964 ↗

NCT06793956 ↗

NCT06667050 ↗

NCT07416890 ↗

NCT05363722 ↗

NCT06431685 ↗

NCT04423185 ↗

NCT04831710 ↗

NCT05024968 ↗

NCT05348811 ↗

NCT07005336 ↗

NCT06583083 ↗

NCT06761846 ↗

NCT04994210 ↗

NCT05386524 ↗

NCT04174781 ↗

NCT07309952 ↗

NCT05457517 ↗

NCT07398326 ↗

NCT04672369 ↗

NCT03884192 ↗

NCT04906044 ↗

NCT06664996 ↗

NCT04840758 ↗

NCT05627427 ↗

NCT03820596 ↗

NCT04085185 ↗

NCT06204094 ↗

NCT05621499 ↗

NCT05216237 ↗

NCT07714317 ↗

NCT06220552 ↗

NCT03765775 ↗

NCT06549855 ↗

NCT03946969 ↗

NCT06688656 ↗

NCT04411706 ↗

NCT04252365 ↗

NCT06029829 ↗

NCT04877821 ↗

NCT04842565 ↗

NCT06485557 ↗

NCT04861948 ↗

NCT05484024 ↗

NCT03903705 ↗

NCT06015035 ↗

NCT04341857 ↗

NCT07646639 ↗

NCT04297280 ↗

NCT06523049 ↗

NCT07156019 ↗

NCT04954794 ↗

NCT07025889 ↗

NCT05979818 ↗

NCT07654530 ↗

NCT04412408 ↗

NCT06979908 ↗

NCT06244225 ↗

NCT04982939 ↗

NCT05312840 ↗

NCT04124731 ↗

NCT04296786 ↗

NCT04653389 ↗

NCT04745130 ↗

NCT03798743 ↗

NCT05627414 ↗

NCT04177290 ↗

NCT07638631 ↗

NCT04625543 ↗

NCT06108596 ↗

NCT07254858 ↗

NCT06860490 ↗

NCT04023916 ↗

NCT05207735 ↗

NCT05918094 ↗

NCT05008666 ↗

NCT07483567 ↗

NCT04179084 ↗

NCT06692491 ↗

NCT04718909 ↗

NCT05648487 ↗

NCT07574528 ↗

NCT05010681 ↗

NCT05383482 ↗

NCT05004974 ↗

NCT06594692 ↗

NCT05522231 ↗

NCT07692152 ↗

NCT07537946 ↗

NCT04486287 ↗

NCT06748508 ↗

NCT04682249 ↗

NCT05608200 ↗

NCT04181489 ↗

NCT04836728 ↗

NCT07468630 ↗

NCT05749042 ↗

NCT06900218 ↗

NCT06356584 ↗

NCT05804526 ↗

NCT07579247 ↗

NCT07310771 ↗

NCT04180501 ↗

NCT05000892 ↗

NCT06403878 ↗

NCT04518982 ↗

NCT06459921 ↗

NCT04535024 ↗

NCT06747169 ↗

NCT04065282 ↗

NCT04096911 ↗

NCT05199649 ↗

NCT04231370 ↗

NCT05244798 ↗

NCT04065737 ↗

NCT07077512 ↗

NCT03874000 ↗

NCT06313190 ↗

NCT04548440 ↗

NCT05280626 ↗

NCT06718205 ↗

NCT04618367 ↗

NCT07077798 ↗

NCT05277675 ↗

NCT07537972 ↗

NCT07581821 ↗

NCT04220944 ↗

NCT06138028 ↗

NCT04695470 ↗

NCT05098119 ↗

NCT04146831 ↗

NCT05971199 ↗

NCT04282278 ↗

NCT07686796 ↗

NCT04682210 ↗

NCT07394387 ↗

NCT07079410 ↗

NCT07411781 ↗

NCT04722718 ↗

NCT05460195 ↗

NCT07331883 ↗

NCT06329973 ↗

NCT07584018 ↗

NCT05171660 ↗

NCT07410975 ↗

NCT07584135 ↗

NCT05188859 ↗

NCT06391190 ↗

NCT07699757 ↗

NCT05429463 ↗

NCT04353830 ↗

NCT05220267 ↗

NCT07040098 ↗

NCT04279379 ↗

NCT05043298 ↗

NCT05472948 ↗

NCT06837948 ↗

NCT06697366 ↗

NCT07487662 ↗

NCT04675983 ↗

NCT05010434 ↗

NCT05113355 ↗

NCT05890742 ↗

NCT04144582 ↗

NCT07157969 ↗

NCT04846452 ↗

NCT04945421 ↗

NCT04659434 ↗

NCT07535632 ↗

NCT05246995 ↗

NCT06618664 ↗

NCT06698757 ↗

NCT06089369 ↗

NCT05166772 ↗

NCT06089382 ↗

NCT05720533 ↗

NCT04612673 ↗

NCT06502080 ↗

NCT07038460 ↗

NCT05002686 ↗

NCT05010668 ↗

NCT03732664 ↗

NCT03700476 ↗

NCT05450029 ↗

NCT06364826 ↗

NCT03830411 ↗

NCT05640609 ↗

NCT06285019 ↗

NCT04356872 ↗

NCT03794440 ↗

NCT04427774 ↗

NCT05495152 ↗

NCT06347198 ↗

NCT03745170 ↗

NCT05244213 ↗

NCT04127227 ↗

NCT04026841 ↗

NCT06421298 ↗

NCT04813406 ↗

NCT04843943 ↗

NCT04189094 ↗

NCT06479759 ↗

NCT06152978 ↗

NCT03975270 ↗

NCT03940001 ↗

NCT05992584 ↗

NCT07016737 ↗

NCT04140318 ↗

NCT07457281 ↗

NCT06497985 ↗

NCT04271813 ↗

NCT03989336 ↗

NCT04072679 ↗

NCT06357806 ↗

NCT06652412 ↗

NCT05174325 ↗

NCT04599790 ↗

NCT07656766 ↗

NCT07490262 ↗

NCT04917770 ↗

NCT05617430 ↗

NCT06454435 ↗

NCT05026593 ↗

NCT06447636 ↗

NCT04769908 ↗

NCT05026736 ↗

NCT04672356 ↗

NCT06141109 ↗

NCT05306847 ↗

NCT07127497 ↗

NCT06240689 ↗

NCT06564298 ↗

NCT05632939 ↗

NCT04840290 ↗

NCT06463834 ↗

NCT07324824 ↗

NCT03619824 ↗

NCT07603661 ↗

NCT06773312 ↗

NCT06241469 ↗

NCT06788171 ↗

NCT04770207 ↗

NCT05088967 ↗

NCT06888648 ↗

NCT05165407 ↗

NCT05530785 ↗

NCT03574402 ↗

NCT05039658 ↗

NCT03629925 ↗

NCT05105672 ↗

NCT05337267 ↗

NCT06956716 ↗

NCT03748134 ↗

NCT06787911 ↗

NCT05118334 ↗

NCT07638501 ↗

NCT05201859 ↗

NCT05843292 ↗

NCT04735861 ↗

NCT03936452 ↗

NCT07594925 ↗

NCT03987867 ↗

NCT04691388 ↗

NCT05928897 ↗

NCT05461235 ↗

NCT05204173 ↗

NCT05357846 ↗

NCT07007767 ↗

NCT06739161 ↗

NCT04918628 ↗

NCT05218148 ↗

NCT06742411 ↗

NCT06812039 ↗

NCT07643623 ↗

NCT05017103 ↗

NCT05245916 ↗

NCT07022301 ↗

NCT04267549 ↗

NCT06308939 ↗

NCT07509424 ↗

NCT07621562 ↗

NCT04258111 ↗

NCT06904014 ↗

NCT07014215 ↗

NCT04724239 ↗

NCT04194359 ↗

NCT05593458 ↗

NCT06341595 ↗

NCT05982301 ↗

NCT06558227 ↗

NCT05177068 ↗

NCT06413342 ↗

NCT06608537 ↗

NCT05339581 ↗

NCT04044222 ↗

NCT04781413 ↗

NCT07194005 ↗

NCT05527821 ↗

NCT07178340 ↗

NCT05279677 ↗

NCT04567069 ↗

NCT07306663 ↗

NCT06841159 ↗

NCT07670026 ↗

NCT05236972 ↗

NCT06487715 ↗

NCT07492615 ↗

NCT05616390 ↗

NCT06888674 ↗

NCT06995105 ↗

NCT07658872 ↗

NCT05849246 ↗

NCT07669740 ↗

NCT04072107 ↗

NCT07088731 ↗

NCT07459296 ↗

NCT05119998 ↗

NCT05594381 ↗

NCT06161909 ↗

NCT05648071 ↗

NCT06776757 ↗

NCT06221462 ↗

NCT04602013 ↗

NCT06090656 ↗

NCT06931808 ↗

NCT05427487 ↗

NCT06091423 ↗

NCT04961515 ↗

NCT05976568 ↗

NCT05839275 ↗

NCT04263870 ↗

NCT04940546 ↗

NCT06198907 ↗

NCT07371611 ↗

NCT04371796 ↗

NCT04718415 ↗

NCT07263386 ↗

NCT06555471 ↗

NCT06046963 ↗

NCT06490341 ↗

NCT04042805 ↗

NCT05214339 ↗
Known as ANTI-PD-1 MONOCLONAL ANTIBODY IBI308 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297829 ↗
Known as Darbersol “fixed dose of either terriplizumab injection (Toripalimab) or Sintilimab injection (Darbersol, Sintilimab).” NCT06078670 ↗
Known as IBI308 “CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable...” NCT03884192 ↗
23

“whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).” NCT06584032 ↗

“Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle” NCT03765775 ↗

“Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody.” NCT05171660 ↗

“Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC” NCT04371796 ↗

“Sintilimab (IBI308) is a monoclonal antibody targeting programmed death-1 (PD-1).” NCT04089657 ↗

“IBI308: 200mg on day1 of each cycle, 3 cycles” NCT04833387 ↗

“Humanized PD-1 antibody (Sintilimab, IBI308)” NCT04194359 ↗

“Sintilimab (IBI308) 200mg IV Q3W” NCT03228836 ↗

“IBI308 IV 200mg Q3W Day1” NCT05164458 ↗

“IBI308 200mg/3 weeks” NCT03114683 ↗

“Sintilimab (IBI308)” NCT05572463 ↗

“other name: IBI308” NCT04065737 ↗

NCT04056949 ↗

NCT03568539 ↗

NCT04401813 ↗

NCT02937116 ↗

NCT06321913 ↗

NCT04277663 ↗

NCT03732430 ↗

NCT03628521 ↗

NCT03872661 ↗

NCT03116152 ↗

NCT03150875 ↗
Known as PD1 antibody ClinicalTrials.gov intervention name — accepted as the source's own label NCT03393416 ↗
3

NCT03975036 ↗

NCT03780634 ↗

NCT06455124 ↗
Known as Sin “OBJECTIVES: ORIENT-16, a phase III clinical trial conducted at 62 hospitals in China, reported that add-on sintilimab (Sin) to chemotherapy (Chemo) had favorable efficacy...” PMID 38594905 ↗ Apr 2024
Known as Sindilizumab “Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody” NCT06620822 ↗
Known as Sintilimab (IBI308) “Sintilimab (IBI308)” NCT05572463 ↗
Known as Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel ClinicalTrials.gov intervention name — accepted as the source's own label NCT06454435 ↗
Known as Sintilimab Injection “200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.” NCT03958097 ↗
2

“Sintilimab Injection” NCT07319429 ↗

“Sintilimab injection” NCT05809336 ↗
Known as sintilizumab “Received IBI310 combined with sintilizumab 200mg” NCT04401813 ↗
Known as Tyvyt “This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants...” NCT07521852 ↗
3

“CIT (chemoimmunotherapy): anti-PD-1 sintilimab (Tyvyt) 200 mg IV on Day 1 q3w combined with platinum-based doublet chemotherapy” NCT04702009 ↗

“Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.” NCT05648487 ↗

“Tyvyt” NCT04096690 ↗
Action Inhibit “This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma...” PMID 34702811 ↗ Oct 2021
Modality Monoclonal antibody “Neoadjuvant Sintilimab (PD-1 Antibody)-Chemotherapy” NCT03619824 ↗
Route Intravenous “Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks” NCT02937116 ↗
Target PDCD1 “anti-programmed death 1 antibody” PMID 32781263 ↗ Aug 2020